Italian biotech company specialized in production of innovative recombinant lytic enzymes is looking to join a consortium for Horizon Europe call

Italian biotech SME committed to R&D, production and marketing of high quality lytic enzymes for cell therapy and regenerative medicine, currently offers services in particular screening and characterization of enzymes, engineering and development of novel recombinant proteins, in vitro and in vivo animal models for testing advanced therapies and medical devices. The company is looking to join a Horizon Europe research consortium under a research cooperation agreement.

The Italian biotech innovative-SME is composed by a multidisciplinary team of qualified scientists and professionals that works and cooperates with national and international societies including the Diabetes Research Institute of Miami, Niguarda Ca’ Granda Hospital, CNR-IAMC and the University of Palermo. The company is committed to R&D, production and marketing of innovative and high quality lytic enzymes, mainly utilized in the field of tissue dissociation for cell therapy and regenerative medicine. Difficulties in obtaining reproducible protocols and results are nowadays addressed as one of the major obstacles against regenerative medicine and advanced therapies successful applications. The SME has developed a key technology platform patenting a highly performant production process of recombinant proteins, synthesizing innovative recombinant collagenases in E.Coli and strong standardized pre-clinical isolation protocol to extract primary cells and stem cells from several tissues. The products are available in vials in different formats as lyophilized powder and in kit packages ready-to-use, with distributors partnership for UK/Ireland; Switzerland and Germany; Israel ; USA and Canada, China and Japan. The company is also partner in H2020 projects: one of the granted projects aims to improve pancreatic islet transplant therapy for T1D; another one, aims on best practice for cell isolation in drug screening platforms; and the last one, is focused on the production of low-cost and highly efficient LEDs, using artificial fluorescent proteins. With experience as production, screening and characterization of recombinant proteins, in vitro and in vivo animal models, with clients at national and international locations, the company wants to expand its international activities in Europe under research and cooperation agreements and join a Horizon Europe research consortium.